The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs

Up to date, preclinical screening for new antiepileptic substances is performed by a combination of different in vivo models of acute seizures, for which large numbers of animals are necessary. So far, little attention has been paid to in vitro models, which are also able to detect antiepileptic eff...

Full description

Bibliographic Details
Main Authors: Hanno Heuzeroth, Matthias Wawra, Pawel Fidzinski, Ramazan Dag, Martin Holtkamp
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2019.00677/full
_version_ 1818020930823127040
author Hanno Heuzeroth
Matthias Wawra
Pawel Fidzinski
Ramazan Dag
Martin Holtkamp
author_facet Hanno Heuzeroth
Matthias Wawra
Pawel Fidzinski
Ramazan Dag
Martin Holtkamp
author_sort Hanno Heuzeroth
collection DOAJ
description Up to date, preclinical screening for new antiepileptic substances is performed by a combination of different in vivo models of acute seizures, for which large numbers of animals are necessary. So far, little attention has been paid to in vitro models, which are also able to detect antiepileptic efficacy and in principle could likewise serve for exploratory preclinical screening. One of the established in vitro models of acute seizures is the 4-aminopyridine (4-AP) model. Previous studies have shown that the 4-AP model is capable to recapitulate the antiepileptic efficacy of standard antiepileptic drugs (AEDs) such as valproate or carbamazepine. Here, we employed a dual methodological approach using electrophysiology and optical imaging to systematically test the antiepileptic efficacy of three new-generation AEDs with distinct mechanisms of action (lacosamide, zonisamide, and levetiracetam). We found that frequency of 4-AP induced seizure like events (SLE) was the most sensitive parameter to detect dose-dependent antiepileptic effects in these compounds. Specifically, levetiracetam reduced SLE frequency while lacosamide and zonisamide at higher doses completely blocked SLE incidence. Analysis of the intrinsic optical signal additionally revealed a subiculum-specific reduction of the area involved in the propagation of ictal activity when lacosamide or zonisamide were administered. Taken together, our data adds some evidence that acute seizure models in vitro are in principle capable to detect antiepileptic effects across different mechanisms of action with efficacy similar to acute models in vivo. Further studies with negative controls, e.g., penicillin as a proconvulsant, and other clinically relevant AEDs are needed to determine if this acute in vitro model might be useful as exploratory screening tool. In view of the increasing sensitivity toward animal welfare, an affective in vitro model may help to reduce the number of laboratory animals deployed in burdening in vivo experiments and to preselect substances for subsequent testing in time- and cost-laborious models of chronic epilepsy.
first_indexed 2024-04-14T08:12:06Z
format Article
id doaj.art-b23df167ea944a27b110a4f39380ce38
institution Directory Open Access Journal
issn 1662-453X
language English
last_indexed 2024-04-14T08:12:06Z
publishDate 2019-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neuroscience
spelling doaj.art-b23df167ea944a27b110a4f39380ce382022-12-22T02:04:31ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2019-06-011310.3389/fnins.2019.00677456175The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic DrugsHanno HeuzerothMatthias WawraPawel FidzinskiRamazan DagMartin HoltkampUp to date, preclinical screening for new antiepileptic substances is performed by a combination of different in vivo models of acute seizures, for which large numbers of animals are necessary. So far, little attention has been paid to in vitro models, which are also able to detect antiepileptic efficacy and in principle could likewise serve for exploratory preclinical screening. One of the established in vitro models of acute seizures is the 4-aminopyridine (4-AP) model. Previous studies have shown that the 4-AP model is capable to recapitulate the antiepileptic efficacy of standard antiepileptic drugs (AEDs) such as valproate or carbamazepine. Here, we employed a dual methodological approach using electrophysiology and optical imaging to systematically test the antiepileptic efficacy of three new-generation AEDs with distinct mechanisms of action (lacosamide, zonisamide, and levetiracetam). We found that frequency of 4-AP induced seizure like events (SLE) was the most sensitive parameter to detect dose-dependent antiepileptic effects in these compounds. Specifically, levetiracetam reduced SLE frequency while lacosamide and zonisamide at higher doses completely blocked SLE incidence. Analysis of the intrinsic optical signal additionally revealed a subiculum-specific reduction of the area involved in the propagation of ictal activity when lacosamide or zonisamide were administered. Taken together, our data adds some evidence that acute seizure models in vitro are in principle capable to detect antiepileptic effects across different mechanisms of action with efficacy similar to acute models in vivo. Further studies with negative controls, e.g., penicillin as a proconvulsant, and other clinically relevant AEDs are needed to determine if this acute in vitro model might be useful as exploratory screening tool. In view of the increasing sensitivity toward animal welfare, an affective in vitro model may help to reduce the number of laboratory animals deployed in burdening in vivo experiments and to preselect substances for subsequent testing in time- and cost-laborious models of chronic epilepsy.https://www.frontiersin.org/article/10.3389/fnins.2019.00677/full4-aminopyridinelevetiracetamlacosamidezonisamidein vitro
spellingShingle Hanno Heuzeroth
Matthias Wawra
Pawel Fidzinski
Ramazan Dag
Martin Holtkamp
The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
Frontiers in Neuroscience
4-aminopyridine
levetiracetam
lacosamide
zonisamide
in vitro
title The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
title_full The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
title_fullStr The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
title_full_unstemmed The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
title_short The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs
title_sort 4 aminopyridine model of acute seizures in vitro elucidates efficacy of new antiepileptic drugs
topic 4-aminopyridine
levetiracetam
lacosamide
zonisamide
in vitro
url https://www.frontiersin.org/article/10.3389/fnins.2019.00677/full
work_keys_str_mv AT hannoheuzeroth the4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT matthiaswawra the4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT pawelfidzinski the4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT ramazandag the4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT martinholtkamp the4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT hannoheuzeroth 4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT matthiaswawra 4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT pawelfidzinski 4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT ramazandag 4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs
AT martinholtkamp 4aminopyridinemodelofacuteseizuresinvitroelucidatesefficacyofnewantiepilepticdrugs